Galantamine — Razadyne — has a mechanistic feature the other AChEIs don't: in addition to inhibiting acetylcholinesterase, it acts as a positive allosteric modulator at nicotinic acetylcholine receptors. The nicotinic modulation enhances the response to ACh at those receptors, theoretically providing a second pathway to cognitive benefit beyond simple ACh preservation.
- Class
- Acetylcholinesterase inhibitor + nicotinic allosteric modulator
- Mechanism
- AChE inhibition + positive allosteric modulation of nicotinic acetylcholine receptors (enhances response to ACh)
- Typical dose
- IR 4-12 mg BID; ER 8-24 mg daily
- Half-life
- ~7 hours
- FDA indications
- Mild to moderate Alzheimer's disease
- Key adverse effects
- GI (similar to other AChEIs), bradycardia, syncope, headache, fatigue
Additional nicotinic modulation theoretically distinguishes from donepezil/rivastigmine — clinical benefit similar. Both IR and ER formulations. CYP2D6 metabolism — poor metabolizers may have higher exposure.
Whether the dual mechanism translates into clinically meaningful superiority is debated. Trial data suggest similar effect sizes to donepezil and rivastigmine. In practice, galantamine is typically positioned as an alternative when donepezil or rivastigmine has failed or caused intolerable side effects, rather than as first-line.
Galantamine adds a second mechanism to cholinesterase inhibition — allosteric modulation of nicotinic receptors — theorized to enhance its cholinergic effect.
Mechanism note: Galantamine's dual mechanism — cholinesterase inhibition plus nicotinic allosteric modulation — is conceptually distinctive, but in practice it behaves much like the other cholinesterase inhibitors.
Formulations: immediate-release dosed BID and extended-release dosed once daily. ER is preferred for adherence. Slow titration over weeks is required to reduce GI side effects.
Metabolism by CYP2D6 and CYP3A4 means inter-patient variation in plasma levels. Poor CYP2D6 metabolizers may have higher exposure and more side effects. Drug interactions via 2D6 and 3A4 are relevant.
Side effects share the AChEI class profile — GI prominent during titration, vivid dreams, bradycardia, urinary effects. Generally comparable to the other AChEIs.
- Cost
- Generic: ~$30-60/month.
- Generic status
- Generic since 2008.
- Formulary typical
- Tier 1-2 generic.
- Access friction
- Minimal.
Prescriber tip: Less commonly chosen than donepezil. ER once-daily formulation eases adherence; immediate-release BID rarely used now.
Galantamine occupies a useful niche position. For the patient where donepezil or rivastigmine has not worked or caused problems, galantamine is a reasonable next step. For first-line AChEI choice, the simpler track record of donepezil is usually the starting point.